TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
HHS announced an interim policy under which it does not intend to take enforcement action against certain licensed pharmacies and physicians compounding six peptides under specified conditions. The policy is not FDA approval; oncologist Gilberto de Lima Lopes Jr. says safeguards may reduce product-quality risks but cannot establish that the substances are safe or effective.
The U.S. Department of Health and Human Services announced an interim enforcement-discretion policy on Oct. 28 covering six peptides compounded by licensed pharmacies and physicians under specified conditions, opening a regulatory path to wider access while the Food and Drug Administration considers formal rulemaking. In a Nov. 10 opinion article for MedPage Today, oncologist Gilberto de Lima Lopes Jr. warned that the policy is not FDA approval and does not establish that the substances are safe or effective.
The six peptides named in the policy are BPC-157, MOTS-c, TB-500, KPV, Semax and Epitalon. HHS said it does not intend to take enforcement action against covered compounding by licensed providers when specified conditions are met. The policy includes requirements related to ingredient sourcing, identity and purity documentation, single-ingredient preparations, labeling, serious adverse-event reporting and patient-specific prescriptions.
De Lima Lopes, an oncologist who says he has spent much of his career conducting cancer trials, acknowledges that these safeguards could address some problems in a market where patients already obtain experimental substances through poorly regulated online suppliers. But he stresses that product controls are not clinical evidence: a certificate of analysis cannot show that a peptide works, and a prescription does not establish a favorable balance of benefit and risk.
The policy followed a July meeting of the FDA’s Pharmacy Compounding Advisory Committee. The committee voted eight to six, with one abstention, to recommend BPC-157 for the compounding list and endorsed five of the other six substances considered. FDA reviewers had a different assessment: briefing documents found insufficient evidence to support adding any of the seven substances reviewed. For BPC-157, they could not establish effectiveness for ulcerative colitis; human safety studies for several others were absent or extremely limited, and reviewers raised product-characterization concerns.
Access Expands Ahead of Clinical Evidence
The policy matters because it could make specified compounded peptides more accessible through licensed providers even though the available evidence does not establish their safety and effectiveness. That may offer patients an alternative to products from poorly regulated online sellers, but regulated compounding is not the same as an approved medicine. Patients and clinicians could mistake tighter sourcing and labeling rules for proof that a product benefits a particular condition.
De Lima Lopes also points to a potential oncology concern, while carefully distinguishing it from a demonstrated harm. Experimental studies suggest BPC-157 may stimulate angiogenesis, the formation of blood vessels, through pathways including VEGFR2 and endothelial nitric oxide synthase. Tumors can use angiogenesis to support growth, but there is no human evidence in the cited material that BPC-157 causes cancer or promotes tumor progression. The concern, he argues, is that possible effects—particularly with prolonged exposure or in people with current or previously treated cancer—have not been definitively assessed.
He also warns against assuming that evidence for one use transfers to another. The FDA review considered BPC-157 for ulcerative colitis, while commercial interest often concerns tendon injuries, exercise recovery and anti-aging. Different indications, doses, routes and durations can change the questions researchers need to answer. Evidence for one condition does not establish benefit or safety for another.
Products Worth Considering
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
Levoit Core 300S-P Smart Air Purifier
Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
From Compounding Review to HHS Policy
The FDA advisory committee discussion and the HHS announcement are separate steps in a continuing regulatory process. The committee made recommendations after considering seven substances; FDA reviewers presented concerns about evidence and product characterization. HHS later set out an interim enforcement approach for six named peptides while the FDA considers formal rulemaking. The supplied account does not describe the policy as an FDA determination that the substances are approved or proven treatments.
De Lima Lopes grounds his caution in the distinction between promising biological ideas and demonstrated patient benefit. He says he has seen experimental mechanisms fail to translate into effective treatments and unexpected toxicities emerge after therapies enter routine practice. He argues that clinical development is slow and can disappoint, but trials are how researchers test whether a treatment works and identify risks. His position is to make review more efficient, not bypass it.
He also describes an indication mismatch: a substance’s proposed biological activity, or results from experimental research, cannot by itself answer whether a specific formulation and regimen helps people. Research into longevity-related biology may offer opportunities, he writes, but results in mice do not establish human benefit.
Safety Signals Still Need Investigation
The cited information does not establish whether any of the six peptides provides a clinical benefit, or define the risks across different doses, routes, treatment durations and patient groups. It also does not clarify what further conditions or restrictions may emerge through FDA rulemaking. The interim policy is not an FDA finding of safety or effectiveness, and the cited account does not report final formal rules.
A separate incident illustrates the difficulty of identifying product-related risks. On July 13, 2025, two women were taken to hospitals after receiving injections containing experimental peptides at a Las Vegas conference booth. Both became seriously ill, required ventilators and later recovered. Nevada regulators imposed $35,000 in fines on four parties, according to the source article. Investigators could not obtain the injected products for laboratory testing, could not verify their exact contents and could not establish what caused the reactions. That episode does not show that the six peptides in the HHS policy caused the illnesses.
For the oncology concern, the available account says experimental studies suggest a possible mechanism but offers no human evidence that BPC-157 causes or advances cancer. The possibility has not been definitively excluded, either. That is an unresolved question, not proof of harm.
FDA Rulemaking and Better Trials
The next regulatory milestone is the FDA’s consideration of formal rulemaking; the source material does not give a completion date or say what final requirements will be adopted. Until then, HHS’s stated policy applies to covered compounding under its specified conditions. Patients and clinicians should distinguish the policy’s manufacturing and reporting safeguards from evidence that a peptide works for a given use.
De Lima Lopes argues that the relevant evidence must answer separate questions: whether a product is what it claims to be, whether it is safe, and whether it benefits patients. Ingredient controls and testing can address product identity and purity; toxicology and clinical studies assess safety; well-designed trials test benefit. Adverse-event reporting can flag problems but cannot replace prospective safety studies.
Further human research would also be needed to assess possible effects in people with existing or previously treated cancers and to test claims tied to different indications. The source article does not report planned trials or a timeline for such studies. For now, the central unresolved issue is whether wider access will be matched by evidence that clarifies who may benefit, under what conditions, and with what risks.
Key Questions
What did HHS announce?
HHS announced an interim enforcement-discretion policy for specified compounding of BPC-157, MOTS-c, TB-500, KPV, Semax and Epitalon by licensed pharmacies and physicians under stated conditions, while the FDA considers formal rulemaking.
Does the policy mean the peptides are FDA-approved?
No. The policy is not FDA approval and does not establish that the substances are safe or effective. HHS described an enforcement approach for certain compounding, not a finding that the peptides are proven treatments.
What is the oncologist’s concern about BPC-157 and cancer?
De Lima Lopes says experimental studies suggest BPC-157 may affect angiogenesis, a process tumors can use to support growth. He also says there is no human evidence that it causes cancer or promotes tumor progression; whether such effects can be definitively excluded remains unclear.
What did the FDA reviewers say about the evidence?
FDA briefing documents found insufficient evidence to support adding any of the seven substances reviewed. Reviewers could not establish BPC-157’s effectiveness for ulcerative colitis and reported absent or very limited human safety studies for several other substances.
Source: medpagetoday.com
